Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors

Pazopanib is US FDA approved for the treatment of advanced soft tissue sarcomas. All patients with this disease ultimately develop resistance to therapy. Mechanisms of resistance include activation of the mTOR, histone deacetylase (HDAC), MAPK, and ERBB4 pathways. We hypothesized that combining pazo...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Sci Rep
Main Authors: Dembla, Vikas, Groisberg, Roman, Hess, Ken, Fu, Siqing, Wheler, Jennifer, Hong, David S., Janku, Filip, Zinner, Ralph, Piha-Paul, Sarina Anne, Ravi, Vinod, Benjamin, Robert S., Patel, Shreyaskumar, Somaiah, Neeta, Herzog, Cynthia E., Karp, Daniel D., Roszik, Jason, Meric-Bernstam, Funda, Subbiah, Vivek
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group UK 2017
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5698336/
https://ncbi.nlm.nih.gov/pubmed/29162825
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-017-13114-8
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares